% | $
Quotes you view appear here for quick access.

ZELTIQ Aesthetics, Inc. Message Board

  • wavesearcher99 wavesearcher99 Nov 21, 2013 10:12 PM Flag

    we may never achieve profitability-says so in prospectus-lotsa luck with this one

    Risks Related to Our Business
    We have limited operating experience and a history of net losses, and we may never achieve or maintain profitability.
    We have a limited operating history, with our first commercial sales of CoolSculpting for the selective reduction of fat in the United States occurring in late 2010. We have incurred significant net losses since our inception, including net losses of approximately $30.1 million in 2012 and $9.6 million in 2011. Our net loss for the nine months ended September 30, 2013, was $13.9 million, and as of September 30, 2013, we had an accumulated deficit of $127.7 million. We will continue to incur significant expenses for the foreseeable future as we expand our sales and marketing, research and development, and clinical and regulatory activities. We may never generate sufficient revenues to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability. Further, because of our limited operating history and because the market for aesthetic products is rapidly evolving, we have limited insight into the trends or competitive products that may emerge and affect our business. We may make errors in predicting and reacting to relevant business trends, which could harm our business. We may not be able to successfully address any or all of these risks, and the failure to adequately do so could cause our business, results of operations, and financial condition to suffer.
    We may not be able to correctly estimate or control our future operating expenses, which could lead to cash shortfalls.
    Our operating expenses may fluctuate significantly in the future as a result of a variety of factors, many of which are outside of our control. These factors include:

    our commercialization strategy;

    the time, resources, and expense required to develop and conduct clinical trials and seek additional regulatory clearances and approvals for additional treatment indications for CoolScul

    Sentiment: Strong Sell

40.24+0.31(+0.78%)Sep 23 4:00 PMEDT